ScholarIQanswers from OpenAlex & ORCID
Nirali N. Shah
ResearcherPublications, citations & collaboration network
Nirali N. Shah is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nirali N. Shah have?
ScholarIQindexed works
Nirali N. Shah has 427 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nirali N. Shah have?
ScholarIQcitation count
Nirali N. Shah has 16,419 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nirali N. Shah?
ScholarIQh-index
Nirali N. Shah has an h-index of 54 in OpenAlex.
What is the i10-index of Nirali N. Shah?
ScholarIQi10-index
Nirali N. Shah has an i10-index of 173 in OpenAlex.
What is the ORCID of Nirali N. Shah?
ScholarIQorcid
The ORCID for Nirali N. Shah is on the source record.
What is the OpenAlex record for Nirali N. Shah?
ScholarIQopenalex
The OpenAlex for Nirali N. Shah is on the source record.
What are the most-cited papers on Nirali N. Shah?
ScholarIQmost cited works
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, Yongzhi Cui, Cindy Delbrook, Steven A. Feldman, Terry J. Fry, Rimas J. Orentas, Marianna Sabatino, Nirali N. Shah, Seth M. Steinberg, D. Stroncek, Nick Tschernia, Constance M. Yuan, Hua Zhang, Ling Zhang, Steven A. Rosenberg, Alan S. Wayne, Crystal L. Mackall
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler‐Stevenson, Constance M. Yuan, Sneha Ramakrishna, Pamela L. Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates, Haneen Shalabi, Thomas J. Fountaine, Jack F. Shern, Robbie G. Majzner, David F. Stroncek, Marianna Sabatino, Yang Feng, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen, Haiying Qin, Boro Dropulić, Daniel W Lee, Crystal L. Mackall
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah, Steven L. Highfill, Haneen Shalabi, Bonnie Yates, Jianjian Jin, Pamela L. Wolters, Amanda K. Ombrello, Seth M. Steinberg, Staci Martin, Cindy Delbrook, Leah Hoffman, Lauren Little, Anusha Ponduri, Haiying Qin, Haris Qureshi, Alina Dulau‐Florea, Dalia Salem, Hao‐Wei Wang, Constance M. Yuan, Maryalice Stetler‐Stevenson, Sandhya R. Panch, Minh Tran, Crystal L. Mackall, David F. Stroncek, Terry J. Fry
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
Nirali N. Shah, Daniel W. Lee, Bonnie Yates, Constance M. Yuan, Haneen Shalabi, Staci Martin, Pamela L. Wolters, Seth M. Steinberg, Eva H. Baker, Cindy Delbrook, Maryalice Stetler‐Stevenson, Terry J. Fry, David F. Stroncek, Crystal L. Mackall
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner, Enrico Fritsche, Michael A. Pulsipher, Nabil Ahmed, Mohamad Hamieh, Meenakshi Hegde, Marco Ruella, Barbara Savoldo, Nirali N. Shah, Cameron J. Turtle, Alan S. Wayne, Mohamed Abou‐El‐Enein